Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3291MR)

This product GTTS-WQ3291MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3291MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15525MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ15034MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ15777MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ10172MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ6430MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ2803MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ7081MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ3891MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW